

Species Used for Drug Testing Reveal Different Inhibition Susceptibility for 17beta-Hydroxysteroid Dehydrogenase Type 1

Gabriele Möller¹, Bettina Husen^{2#a}, Dorota Kowalik¹, Leena Hirvelä³, Dariusz Plewczynski⁴, Leszek Rychlewski⁵, Josef Messinger², Hubert Thole², Jerzy Adamski^{1,6,*#b}

1 Helmholtz Zentrum München, Institute of Experimental Genetics, Genome Analysis Center, Neuherberg, Germany, **2** Solvay Pharmaceuticals Research Laboratories, Hannover, Germany, **3** Hormos Medical, Turku, Finland, **4** Interdisciplinary Centre for Mathematical and Computational Modelling, Warsaw University, Warsaw, Poland, **5** Bioinfobank Institute, Poznań, Poland, **6** Lehrstuhl für Experimentelle Genetik, Technische Universität München, Freising-Weihenstephan, Germany

Abstract

Steroid-related cancers can be treated by inhibitors of steroid metabolism. In searching for new inhibitors of human 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD 1) for the treatment of breast cancer or endometriosis, novel substances based on 15-substituted estrone were validated. We checked the specificity for different 17β-HSD types and species. Compounds were tested for specificity *in vitro* not only towards recombinant human 17β-HSD types 1, 2, 4, 5 and 7 but also against 17β-HSD 1 of several other species including marmoset, pig, mouse, and rat. The latter are used in the processes of pharmacophore screening. We present the quantification of inhibitor preferences between human and animal models. Profound differences in the susceptibility to inhibition of steroid conversion among all 17β-HSDs analyzed were observed. Especially, the rodent 17β-HSDs 1 were significantly less sensitive to inhibition compared to the human ortholog, while the most similar inhibition pattern to the human 17β-HSD 1 was obtained with the marmoset enzyme. Molecular docking experiments predicted estrone as the most potent inhibitor. The best performing compound in enzymatic assays was also highly ranked by docking scoring for the human enzyme. However, species-specific prediction of inhibitor performance by molecular docking was not possible. We show that experiments with good candidate compounds would out-select them in the rodent model during preclinical optimization steps. Potentially active human-relevant drugs, therefore, would no longer be further developed. Activity and efficacy screens in heterologous species systems must be evaluated with caution.

Citation: Möller G, Husen B, Kowalik D, Hirvelä L, Plewczynski D, et al. (2010) Species Used for Drug Testing Reveal Different Inhibition Susceptibility for 17beta-Hydroxysteroid Dehydrogenase Type 1. PLoS ONE 5(6): e10969. doi:10.1371/journal.pone.0010969

Editor: Ulrich Zanger, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Germany

Received: February 19, 2010; **Accepted:** May 10, 2010; **Published:** June 8, 2010

Copyright: © 2010 Möller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The consensus docking part of the manuscript was supported by the OxyGreen (KBBE-2007-212281) project as well as the Polish Ministry of Education and Science (PBZ-MNII-2/1/2005, N N301 159735). The work of DP was supported by Polish Ministry of Science and Higher Education N301 159735 grant. This work was further supported by the Helmholtz Zentrum München and Solvay Pharmaceutical Research Laboratories. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. However, the manuscript was cleared for submission under the funder's manuscript approval standard operating procedures.

Competing Interests: BH, JM and HT are employed by Solvay Pharmaceuticals Research Laboratories, and LH is employed by Hormos Medical. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.

* E-mail: adamski@helmholtz-muenchen.de

#a Current address: Abbott, Hannover, Germany

#b Current address: Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Experimental Genetics, Genome Analysis Center, Neuherberg, Germany

Introduction

Human diseases could be treated by selective manipulation of pathways involved in their pathogenesis. Several druggable targets were defined in humans [1,2] including steroid metabolizing enzymes like 17β-hydroxysteroid dehydrogenases (17β-HSDs) controlling the biological potency of steroid hormones by redox reactions at position 17 of the steroid scaffold [3,4,5,6,7]. 17β-HSDs belong to the short-chain dehydrogenase/reductase superfamily (SDR) [8], except for 17β-HSD type 5 which is a member of aldoketoreductase (AKR) superfamily [9].

Since the observation of the prognostic value of 17β-HSDs in breast or prostate cancers [10,11,12,13,14] the research on these enzymes included development of specific inhibitors [15,16,17,18,19,20,21,22,23]. It was assumed that in hormone-dependent cancers an inhibitor of conversion of estrone to

estradiol by 17β-HSD 1 would deplete the biologically active hormone estradiol from the signal transduction pathway and by that constrain cell proliferation in breast cancer or endometriosis. Therefore, extensive strategies included 17β-HSD 1 as a drug target [21,22]. We recently contributed to this field by a development of novel effective inhibitors of this enzyme by exploring modifications at positions 2 or 15 of estrone (compounds **1**, **2** and **3** in this study) [24] and designing fluorine derivatives of estrone [25].

The growing number of genetically and functionally distinct 17β-HSDs makes it difficult to develop enzyme-specific inhibitors. At least fourteen types of 17β-HSDs are known so far with partly overlapping or reciprocal substrate preferences and not always distinct tissue distribution [5,6,7,26,27]. Furthermore, specificity analyses are affected by the nature of assay systems like *in vitro* assays with recombinant protein or *ex vivo* measurements in cell

lines naturally expressing the enzyme. The verification of inhibition results seen for human 17 β -HSDs in animal models, mostly rodents, has to cope with the problem of differences to humans in sex steroid metabolism [28,29,30,31].

In this work we focused on the inhibition of 17 β -HSDs converting estrogens and androgens. We analyzed (i) how susceptible human 17 β -HSD 1, 2, 4, 5 and 7 were to inhibition by a novel class of 15-substituted estrogens described in our patents [24], and (ii) how the candidate inhibitors were modulating the activity of 17 β -HSD 1 from different species including human, marmoset, pig, mouse and rat. Because profound differences between the orthologs in the susceptibility to inhibition were observed, we also analyzed (iii) if molecular docking experiments performed with modeled enzymes can differentiate or predict the efficacy of inhibitors.

Results

Validation of 17 β -HSD Type Specificity

Several types of 17 β -HSDs were chosen to check the specificity of recently developed inhibitors [24] against human 17 β -HSD 1. Structure-function relationships were already reported for these inhibitors [24] and will not be analyzed in this manuscript. We monitored the inhibition at the physiological preferences of the 17 β -HSDs, i.e. reduction of estrone to 17 β -estradiol by 17 β -HSD 1 and 7, the reduction of androstenedione to testosterone by 17 β -HSD 5, and the oxidation of 17 β -estradiol to estrone by types 2 and 4. We restricted our assay to this set of enzymes as they are active after recombinant expression in bacteria and could be used for fast, robust and inexpensive screens of inhibitors. Other 17 β -HSD types require transfection into mammalian cell lines for activity assays (type 3 or 14, [32,33]) or were excluded for being physiologically irrelevant to this study (type 12 [34]).

With this set of recombinant enzymes we have checked the relative inhibition of different reaction directions by 15-substituted estrogens [24] and a 16 β -substituted estrogen [35] (for structures see Figure 1). We observed that compounds number **2** and **3** revealed high inhibition of the human 17 β -HSD 1 reductive activity with very low inhibition of the other human 17 β -HSDs (Figure 2). The substances reached a better selectivity than the Sterix reference compound **5** [35] especially showing less influence on 17 β -HSD 5. However, as illustrated by measurements of our other compounds, not all substitutions at position 15 are very selective. For example substance **4** inhibits 17 β -HSD 5 to the same amount as human 17 β -HSD 1.

Analysis of Inhibitor Influence on Activity of 17 β -HSD 1 in Different Species

We have included all inhibitors in the next testing of susceptibility to inhibition of 17 β -HSD 1 in different species. We prepared a set of recombinant 17 β -HSDs 1 originating from human, marmoset, pig, mouse and rat. These 17 β -HSD 1 enzymes reveal high level of amino acid similarity (Figure 3) ranging from 85% for human-marmoset to 78% for human-rat pairwise comparisons. The most divergent residues of the sequences are located in their C-terminal parts.

Clear differences in the inhibitor influence on activity of 17 β -HSD 1 of different species were observed (Figure 4). Surprisingly, the rodent enzymes revealed the biggest discrepancies to values measured for the human enzymes with all inhibitors. Comparable inhibition efficacy to that of human 17 β -HSD 1 was observed for the marmoset and pig enzymes. To facilitate normalization and direct comparison with published records we included estrone (compound **6**) to our study. The estrone was used because it is a

natural ligand of 17 β -HSD 1 and because it causes substrate inhibition in higher concentrations by a formation of dead-end complex [37]. The estrone turned out to be a potent inhibitor of all tested 17 β -HSD 1 orthologs.

We further checked the inhibition of the best inhibitors, the compounds **2** and **3**, by IC₅₀ determination (Table 1). These data allowed quantification of efficacy of inhibition between 17 β -HSDs 1 of different species. Pig 17 β -HSD 1 is affected by both inhibitors in nearly the same concentration range as the human enzyme. Marmoset monkey 17 β -HSD 1 requires a higher concentration to be blocked. The rodent enzymes were inhibited only up to 10 and 40% by compounds **2** and **3**, respectively. This precluded IC₅₀ determination for the rodent enzymes.

Validation of Candidate Compounds by Molecular Docking

Although the overall amino acid sequences of 17 β -HSD 1 are very similar in different species (Figure 3) some differences are present. These differences lead to structural changes in enzyme substrate binding pocket and therefore add to differences in the potency of inhibitors in the different enzymes. We checked if molecular docking experiments can contribute to the challenge of prediction of inhibitor specificity. Molecular docking is a valuable approach in the analyses of ligand-protein interaction and can be used for pre-selection of pharmacophores as candidates for enzyme inhibitors. To accomplish that we performed docking of inhibitors to models of the different 17 β -HSDs that were also enzymatically tested in this study. Please note that the docking experiments were performed only including most similar parts of enzymes, i.e. taking the amino acid sequence from the N-terminus up to the position marked by an arrow as shown in the Figure 3. The divergent C-terminal parts of proteins were neither used in modeling nor docking studies.

We first performed a global comparison of all enzyme types in all species with known *in vitro* inhibition data. Results of the first round of docking experiments are depicted in the Supporting Information (Table S1). Experimental inhibition effects were available for 49 protein-compound pairs. The absolute correlation between scores predicted by 7 docking programs and measured inhibition ranged between 1% and 36% (AutoDock: 36%, eHits: 26%, Cdocker: 19%, SurFlex: 16%, Dock: 12%, LigFit: 9%, Glide: 1%). Higher docking scores correspond to higher fitting of compounds into the protein structures.

We realized that the correlation in this set of protein-compound pairs should not be used to judge the quality of the docking programs. This is because the correlation varies a lot due to flexibility of both the protein and the compound. However, when applying a consensus mode instead of individual approaches an assessment of 17 β -HSD inhibitors can be gained. When exploring a consensus of the docking methods we observed a correlation of 57%. However, when the jackknife procedure for elimination of training (memorization) effects was employed the correlation coefficient dropped to 32%, which is lower than the best performing method on this set (AutoDock: 36%). A modified consensus method that utilizes only 2 docking programs (AutoDock & eHits) exhibited an improved correlation to 41%, which was better than any single docking method in the set. Only this final method was used for subsequent data analyses. The relation between all predicted and measured inhibition values is visualized in Figure 5.

Next we analyzed data from 17 β -HSDs 1 of different species. For human and marmoset data there is a good correlation between the predicted ranking of compounds as inhibitors by molecular docking scores and measured inhibition efficacy

Compound number	Structure	Reference
1		[24]
2		[24]
3		[24]
4		[36]
5		[35] ^a
6		Estrone ^b

Figure 1. Structures of compounds used in the study. a Sterix compound, b product of estradiol oxidation.
doi:10.1371/journal.pone.0010969.g001




Figure 2. Analysis of inhibitor specificity among different human 17 β -HSD types. Negative values correspond to a weak activation. All assays were run in duplicates of two independent experiments, normalized to control assay and reported as mean values \pm SEM. Inhibitors were tested at 2 μ M final concentration. Structures are shown in Figure 1. For referencing purposes the traditional and new names [8] of different human 17 β -hydroxysteroid dehydrogenase types are given: 17 β -HSD 1 – SDR28C1, 17 β -HSD 2 – SDR9C2, 17 β -HSD 4 – SDR8C1, 17 β -HSD 5 – AKR1C3, 17 β -HSD 7 – SDR37C1.

doi:10.1371/journal.pone.0010969.g002




Figure 3. Amino acid sequence comparison of 17 β -HSDs 1 of different species. Species are given to the left, followed by amino acid residue numbering. Identical amino acid residues are given white on black, whereas similar residues are grey shaded. Arrow points to the last C-terminal amino acid resolved in the crystal structure of PDB entry 1A27.

doi:10.1371/journal.pone.0010969.g003




Figure 4. Inhibitors of activity of 17 β -HSD 1 of different species. Different inhibitors were tested. Estrone (compound 6) was included to check the inhibition by the native substrate. Negative values correspond to a weak activation. All assays were run in duplicates of two independent experiments, normalized to control assay and mean values \pm SEM reported. Inhibitors were tested at 2 μ M final concentration. For structures see Figure 1.

doi:10.1371/journal.pone.0010969.g004

(Table 2). Porcine and rodent enzymes show much less susceptibility to inhibitors and their measured inhibition values reveal less correlation with the corresponding docking scores. For all 5 species models of the 17 β -HSD 1 enzymes the consensus method predicted estrone (compound 6) as the most potent inhibitor (best fitting compound) in agreement with the experimental data (Figure 4 and Table 2). On the average, estrone is the best natural inhibitor for all species studied.

We further analyzed the predictive value of molecular docking for different human 17 β -HSD types. This docking approach ranked compounds 1 and 2 as best *in silico* hits. However, the measured inhibition ranks compounds 2, 3 and 1 as most specific inhibitors of human 17 β -HSDs 1. This observation is based on the lowest inhibition for the human 17 β -HSD 2, 4, 5, and 7 at highest inhibition of 17 β -HSDs 1 (Table 3).

Discussion

Rationale for Inhibitor Search

The development of therapies for estrogen-dependent human diseases addresses the pre-receptor metabolism [38,39,40], which includes inhibition of enzymes like steroid sulfatase (STS), P450 aromatase and 17 β -HSD 1. The design and application of STS

inhibitors [41,42], aromatase inhibitors [43,44,45], and combined STS-aromatase inhibitors [46] are showing significant therapeutic promise. On the other hand, the inhibitors for human 17 β -HSD 1 are still at an early stage of development [34,47,48,49] and have not reached clinical studies yet. Nevertheless, many efforts were undertaken in the finding effective inhibitors for human 17 β -HSD 1 [21]. Selective 17 β -HSD 1 inhibitors were reported with modifications of the steroid scaffold at positions 6, 16 or 17 [16,18,19,50,51,52], substitution with sulfamates [53,54], benzenes [55] or fluorine [25], in form of hybrid inhibitors constituted of estradiol with adenosine [17,56,57] and non-steroidal compounds [58,59,60]. Their activities are already reaching effective and selective inhibition of the human 17 β -HSD 1 with pharmacologically attractive IC₅₀ values in the nanomolar range. Our recent patents on 15-substituted estrone [24,61] contributed to a new direction to this research.

Challenge of Animal Models

Although animal models found broad applications in drug discovery they are not ideal phenocopies of human physiology in health and disease. Both enzyme expression levels and amino acid compositions of homologous enzymes are not the same. Consequently substrate preferences of steroid metabolizing enzymes in humans and other mammalian species are different for estrogens, androgens and glucocorticoids [7,29] and in turn drug susceptibility is expected also to be different. Recently, inhibitors of glucocorticoid metabolism were shown to effect orthologs of different mammalian species [62] to various extent. Similar experiments including several species at the same time were not yet performed. Only one publication addressed the inhibitory potency of putative drugs against estrogenic 17 β -HSDs in rats [31].

Our results now prove that the estrogenic 17 β -HSDs 1 from different species indeed are distinctly affected by inhibitory compounds. Especially the lack of inhibition of the rodent enzymes by the most potent inhibitors of human 17 β -HSD 1 is to be underlined. This is not very surprising since it is well known

Table 1. Comparison of IC₅₀ values obtained for inhibition of 17 β -HSDs 1 in different species.

Compound number	IC ₅₀				
	Human	Marmoset	Pig	Mouse	Rat
2	87.4 nM	3607 μ M	457 nM	nd	nd
3	1.3 nM	95.3 nM	0.34 nM	nd	nd

nd - not to determine, due to too low inhibition.

doi:10.1371/journal.pone.0010969.t001




Figure 5. Relation between the predicted and observed inhibition values. Results are given for a modified consensus method that utilizes only two docking programs AutoDock and eHits.
doi:10.1371/journal.pone.0010969.g005

that rodent steroid metabolism differs from that in humans [28,29,30]. However, we provide a ranking of inhibitor efficacy for enzymes in different species. In case of preclinical animal tests, which are usually performed in mouse or rat, the most potent inhibitory compounds would have been sorted out before entering further development for human application.

Lessons from Docking Experiments

Several novel potential inhibitors for 17β -hydroxysteroid dehydrogenases have been docked using available algorithms but applying a novel set of auxiliary simulation scripts. Although scoring accuracy and range of applications of computational docking has improved in the last years, resulting partially from

Table 2. Comparison of predicted and measured inhibition for 17b-HSD 1 orthologs of five species.

Predicted consensus score						
Species	Compound					
	1	2	3	4	5	6
Human	72.1	53.6	53.6	57.1	58.1	101.3
Marmoset	38.1	45.2	52.5	58.5	35.7	78.1
Mouse	39.2	21.3	22.4	57.1	15.8	94.3
Pig	n.m.	-1.5	24.0	35.0	35.3	74.6
Rat	32.9	32.3	30.9	54.8	27.8	86.7
average:	45.6	30.2	36.7	52.5	34.5	87.0
Observed % inhibition						
Species	Compound					
	1	2	3	4	5	6
Human	63.6	94.7	97.9	95.8	100.0	100.6
Marmoset	30.6	60.3	98.5	85.2	45.6	109.5
Mouse	27.0	-1.5	27.0	18.5	3.2	101.4
Pig	n.m.	67.0	104.7	66.2	95.7	86.3
Rat	47.1	40.3	5.3	19.4	-2.4	79.1
average:	42.1	52.2	66.7	57.0	48.4	95.4

Predicted values correspond to molecular docking scores, observed values are from enzymatic assays at 2 μ M compound concentration, n.m. – not measured.
doi:10.1371/journal.pone.0010969.t002

Table 3. Comparison of predicted and observed inhibition for five compounds and four human 17 β -HSD 1 homologs.

Predicted consensus score					
17 β -HSD type_species ^a	Compound				
	1	2	3	4	5
1_human	72.1	53.6	53.6	57.1	58.1
2_human	40.3	31.3	31.5	83.0	26.5
4_human	18.6	18.7	6.6	75.7	-17.1
5_human	49.3	73.9	62.6	81.7	64.5
7_human	46.3	27.9	54.7	69.5	25.9
Observed % inhibition					
17 β -HSD type_species ^a	Compound				
	1	2	3	4	5
1_human	63.6	94.7	97.9	95.8	100.0
2_human	-4.3	16.7	18.6	-0.3	-3.2
4_human	7.2	0.1	2.1	5.5	5.6
5_human	21.6	33.9	29.3	93.5	50.6
7_human	-3.6	-7.1	-9.0	-5.8	0.0

Predicted values correspond to molecular docking scores, observed values are from enzymatic assays at 2 μ M compound concentration.

^atype of enzyme is separated by underscore from species description.

doi:10.1371/journal.pone.0010969.t003

increasing computing power, this method is far from excellence and still cannot be applied to practical tasks without *in vitro* and *in vivo* validation. Nevertheless, the method was able to confirm the choice of one of the two universal inhibitors and was able to select the most specific human 17 β -HSD 1 inhibitor based on docking results on human 17 β -HSD homologs, despite generally quite low correlation between the docking scores and observed inhibition. However, at present molecular modeling experiments done on modeled enzyme structures should be interpreted with caution.

Closing Remarks

In this work we contributed to the field of inhibitor development in estrogen metabolism by 17 β -HSD 1 by the quantification of inhibitor preferences between human and animal models used in the process of drug screening. Based on our data, steroid metabolism inhibitor development should be validated rather with primates or pig than with rodents. Otherwise, good candidate compounds against human targets would be already out-selected by experiments in the rodent model during pre-clinical optimization steps although they might have been specific and valuable drugs in disease treatment in humans.

Materials and Methods

Compound Synthesis

Compounds were synthesized as described elsewhere [24], compound **5** developed by Sterix (Ipsen SA) was re-synthesized according to [35]. Structures of compounds used for testing are given in Figure 1.

Expression of Recombinant Enzymes in E.coli

Full length cDNAs of several 17 β -HSDs type 1 originating from different species were cloned either into the pQE30 vector (human 17 β -HSD 1, coding for acc. no. NP_000404) for expression as His-Tag protein or into a modified pGex-2T vector [63] (mouse 17 β -HSD 1, acc. no. NP_034605; rat 17 β -HSD 1, acc.

no. NP_036983; marmoset 17 β -HSD 1, acc. no. AAG01115; porcine 17 β -HSD 1, acc. no. NP_001121944) for expression as GST-fusion proteins. The marmoset 17 β -HSD 1 enzyme sequence was updated by the missing N-terminal part (AF272013) and the new porcine sequence was submitted to GenBank (NP_001121944). Human 17 β -HSDs 2, 4, 5 (AKR1C3, the latter kindly provided by Dr. T. Penning) and 7 were all cloned into the modified pGEX-2T vector. For 17 β -HSD 4 only the SDR-domain converting the steroids was subcloned [63]. Plasmids were transformed into *E.coli* BL21 DE3 Codon Plus RP (Stratagene) and enzyme expression was induced by 0.5 mM IPTG. After 4h incubation at 37°C with continuous shaking bacteria were pelleted by centrifugation at 10.000 \times g. Pellets were stored until use at -20°C.

Enzyme Identities

Recently, the international SDR-Initiative has recommended [8] a new nomenclature for the human enzymes analyzed in this study. Here we provide for referencing purposes traditional and new names: 17 β -HSD 1 – SDR28C1, 17 β -HSD 2 – SDR9C2, 17 β -HSD 4 – SDR8C1, 17 β -HSD 5 – AKR1C3, 17 β -HSD 7 – SDR37C1.

In Vitro Measurement of Enzymatic Activity

Catalytic activity towards estrone and estradiol was assessed as originally described [25,64] with minor modifications. The bacteria containing recombinant enzymes were resuspended in PBS and enzymatic assays were performed in 100 mM sodium phosphate buffer at pH 6.6 for the reductive reaction and at pH 7.7 for the oxidative reaction. The concentration of ³H-labelled steroid substrates in the reaction mixtures were 15 nM for estrone (2,4,6,7-³H(N)) in assays of 17 β -HSD 1 and 7), 21 nM for estradiol (6,7-³H(N)) in assays of 17 β -HSD 2 and 4, and 21 nM for androstenedione (1,2,6,7-³H(N)) in assays for 17 β -HSD 5. All substrates were purchased from NEN/Perkin Elmer. The

cofactors NADPH (Sigma; for reductive reactions) and NAD⁺ (Serva, for oxidative reactions) were used at final concentrations of 0.5 mg/ml. Potential inhibitors (dissolved in DMSO) were added in a final concentration of 2 μ M or 0.005 μ M to 5 μ M in case of IC₅₀ determination (1% DMSO final each). The incubation at 37°C was stopped with 0.21 M ascorbic acid in methanol:acetic acid 99:1 (v:v) after the time needed to convert approximately 30% of the substrate in a control assay with 1% DMSO, without inhibitor candidates. Substrates and products were extracted from the reaction mixture by SPE with Strata C18-E columns (Phenomenex), eluted by methanol and separated by RP-HPLC in a Beckman-Coulter system, using the column Luna 5 μ m C18(2), 125 \times 4.0 mm (Phenomenex). The solvent used was acetonitrile:water (43:57, v:v) at a flow rate of 1 ml/min. Radioactivity was detected by online-scintillation counting (Berthold LB506D) after mixing with ReadyFlowIII (Beckman). Conversion was calculated from integration of substrate and product peaks. For calculation of inhibitory potential conversion of control assay (assay without inhibitor) was set to 0% inhibition. All assays were run in duplicates of two independent experiments and mean values are reported. The IC₅₀ values were determined by the One Ligand Binding model of SigmaPlot kinetics module.

Molecular Docking

The docking experiments were performed on 9 protein models, i.e. 17 β -HSD 1 from human, marmoset, mouse, rat and pig, and further 17 β -HSD 2, 4, 5 and 7 from human. Amino acid sequences were aligned with T-coffee [65] and inspected with Boxshade 3.21 (http://www.ch.embnet.org/software/BOX_form.html).

Models were based on the crystal structures deposited in the Protein Data Bank. For the human enzymes 17 β -HSD type 1, 4, and 5 the PDB entries 1A27, 1ZBQ, and 2FGB, respectively, were directly used [66,67,68,69]. If crystal structures were not available, a homology modeling procedure based on aligning the sequence of the target protein with the sequence of the closest homolog deposited in PDB was applied. For 17 β -HSD1 of other species and human 17 β -HSD 2 the template 1A27 was used, for 17 β -HSD7 entry 1N5D served as template. C-terminal parts of the proteins analyzed revealed lower similarities and were not included in the model building. This local dissimilarity a typical effect of SDR-protein family already approached by us in modeling studies [70]. Models were generated automatically using the MODELLER program (modbase.compbio.ucsf.edu/ModWeb20.html/modweb.html).

Docking of compounds was performed using the following 7 docking programs: AutoDock, Cdocker, eHits, LigFit, Dock, Surflex and Glide accessible as described [71]. From each program one final score was selected as estimator of the fitness function and predictor for the experimental inhibition.

References

- Hardy LW, Peet NP (2004) The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. *Drug Discov Today* 9: 117–126.
- Plewczynski D, Rychlewski L (2008) Meta-basic estimates the size of druggable human genome. *J Mol Model* 15: 484–489.
- Vihko P, Harkonen P, Soronen P, Torn S, Herrala A, et al. (2004) 17 β -Hydroxysteroid dehydrogenases—their role in pathophysiology. *Mol Cell Endocrinol* 215: 83–88.
- Luu-The V (2001) Analysis and characteristics of multiple types of human 17 β -hydroxysteroid dehydrogenase. *J Steroid Biochem Mol Biol* 76: 143–151.
- Lukacik P, Kavanagh KL, Oppermann U (2006) Structure and function of human 17 β -hydroxysteroid dehydrogenases. *Mol Cell Endocrinol* 248: 61–71.
- Möller G, Adamski J (2009) Integrated view on 17 β -hydroxysteroid dehydrogenases. *Mol Cell Endocrinol* 301: 7–19.
- Prehn C, Möller G, Adamski J (2009) Recent advances in 17 β -hydroxysteroid dehydrogenases. *J Steroid Biochem Mol Biol* 114: 72–77.
- Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, et al. (2009) The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. *Chem Biol Interact* 178: 94–98.
- Jin Y, Penning TM (2007) Aldo-Keto Reductases and Bioactivation/Detoxication. *Annu Rev Pharmacol Toxicol* 47: 263–292.
- Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, et al. (2004) 17 β -hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. *Cancer Res* 64: 7604–7609.
- Gunnarsson C, Hellqvist E, Stal O (2005) 17 β -Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. *Br J Cancer* 92: 547–552.
- Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stal O (2006) 17 β -hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells

The consensus scoring method was based on multivariate linear regression analysis (least squares method) which assigns coefficients to each of the 7 docking programs to maximize the fitness between a linear combination of the 7 docking scores multiplied by the coefficients (predicted values) and the observed experimental inhibition (observed values). To eliminate the training (memorization) effect a jackknife procedure was employed. The regression analysis for a respective tested compound-protein pair was conducted in this case by using only values obtained for other compound-protein pairs (removing the tested pair from the dataset).

Additionally, a modified consensus method was created that used only scores and correlation coefficients of 2 docking programs (AutoDock and eHits) performing best on our dataset (exhibiting highest correlation between the predicted and observed values) by setting the docking scores of 5 docking methods (Cdocker, LigFit, Dock, Surflex, Glide) to 0.

The estimation of the accuracy of the docking protocol was based on the Pearson correlation coefficient between the predicted score and the observed inhibition. The estimation was conducted also separately for each model and each compound. When assessing the correlation for a protein model only compound-protein pairs with this protein were left in the dataset. Likewise, the correlation for a compound was calculated only on pairs with this compound.

Gene Bank Submissions

The sequence of marmoset 17 β -HSD was extended by the missing N-terminal part (AF272013) and the porcine sequence received acc. no NP_001121944.

Supporting Information

Table S1 Prediction results for inhibitors of different human 17 β -HSD types in different species.

Found at: doi:10.1371/journal.pone.0010969.s001 (0.12 MB DOC)

Acknowledgments

We are thankful to Dr. Trevor Penning (University of Philadelphia, Pennsylvania, USA) for providing the plasmid coding for 17 β -HSD 5 (AKR1C3). We thank Dr. Almuth Einspanier (University of Leipzig, Germany) for marmoset tissue sample.

Author Contributions

Conceived and designed the experiments: GM BH DP LR JM HT JA. Performed the experiments: GM DK DP LR. Analyzed the data: GM JA. Contributed reagents/materials/analysis tools: BH LH JM JA. Wrote the paper: GM LR JA.

- and is a prognostic marker in estrogen receptor-positive breast cancer. *Cancer Res* 66: 11471–11477.
13. Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjöld B, et al. (2008) Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. *Breast Cancer Res Treat* 108: 35–41.
 14. Rasiah KK, Gardiner-Garden M, Padilla EJ, Möller G, Kench JG, et al. (2009) HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. *Mol Cell Endocrinol* 301: 89–96.
 15. Poirier D (2003) Inhibitors of 17beta-hydroxysteroid dehydrogenases. *Curr Med Chem* 10: 453–477.
 16. Lawrence HR, Vicker N, Allan GM, Smith A, Mahon MF, et al. (2005) Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. *J Med Chem* 48: 2759–2762.
 17. Tchadam Ngatcha B, Luu-The V, Labrie F, Poirier D (2005) Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. *J Med Chem* 48: 5257–5268.
 18. Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, et al. (2006) Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. *J Med Chem* 49: 1325–1345.
 19. Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, et al. (2006) Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. *Chem Med Chem* 1: 464–481.
 20. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, et al. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. *J Med Chem* 51: 2158–2169.
 21. Brosic P, Risner TL, Gobec S (2008) Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. *Curr Med Chem* 15: 137–150.
 22. Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, et al. (2008) Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. *Bioorg Med Chem* 16: 4438–4456.
 23. Day JM, Tutill HJ, Purohit A, Reed MJ (2008) Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. *Endocr Relat Cancer* 15: 665–692.
 24. Messinger J, Husen B, Koskimies P, Hirvelä L, Kallio L, et al. (2008) Estrone C15 derivatives—a new class of 17 beta hydroxysteroid dehydrogenase 1 inhibitors. *Molecular and Cellular Endocrinology* 301: 216–224.
 25. Deluca D, Möller G, Rosinus A, Elger W, Hillisch A, et al. (2006) Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. *Mol Cell Endocrinol* 248: 218–224.
 26. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, et al. (2006) Control of cell proliferation by steroids: The role of 17HSDs. *Mol Cell Endocrinol* 248: 141–148.
 27. Luu-The V, Belanger A, Labrie F (2008) Androgen biosynthetic pathways in the human prostate. *Best Pract Res Clin Endocrinol Metab* 22: 207–221.
 28. Preslock JP (1980) A review of in vitro testicular steroidogenesis in rodents, monkeys and humans. *J Steroid Biochem* 13: 965–975.
 29. Peltoketo H, Luu-The V, Simard J, Adamski J (1999) 17beta-hydroxysteroid dehydrogenase (HSD)/17-keto steroid reductase (KSR) family: nomenclature and main characteristics of the 17HSD/KSR enzymes. *Journal of Molecular Endocrinology* 23: 1–11.
 30. Peltoketo H, Nokelainen P, Piao YS, Vihko R, Vihko P (1999) Two 17beta-hydroxysteroid dehydrogenases (17HSDs) of estradiol biosynthesis: 17HSD type 1 and type 7. *J Steroid Biochem Mol Biol* 69: 431–439.
 31. Kruchten P, Werth R, Marchais-Oberwinkler S, Bey E, Ziegler E, et al. (2009) Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations. *C R Chim* 12: 1110–1116.
 32. Geissler W, Davis D, Wu L, Bradshaw K, Patel S, et al. (1994) Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. *Nature Genetics* 7: 34–39.
 33. Lukacik P, Keller B, Bunkoczi G, Kavanagh KL, Lee WH, et al. (2007) Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. *Biochem J* 402: 419–427.
 34. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, et al. (2008) 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. *Int J Cancer* 122: 1931–1940.
 35. Vicker N, Lawrence HRR, Allan GM, Bubert C, Fischer DSM, et al. (2004) 17beta-hydroxysteroid dehydrogenase inhibitors. Patent WO/2004/085457.
 36. Messinger J, Schoen U, Thole H, Husen B, Koskimies P, et al. (2008) Therapeutically active triazoles and their use. Patent US 2008/0146531 A1.
 37. Huang YW, Pineau I, Chang HJ, Azzi A, Bellemare V, et al. (2001) Critical residues for the specificity of cofactors and substrates in human estrogenic 17beta-hydroxysteroid dehydrogenase 1: variants designed from the three-dimensional structure of the enzyme. *Mol Endocrinol* 15: 2010–2020.
 38. Penning TM (2003) Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. *Hum Reprod Update* 9: 193–205.
 39. Penning TM, Jin Y, Rizner TL, Bauman DR (2008) Pre-receptor regulation of the androgen receptor. *Mol Cell Endocrinol* 281: 1–8.
 40. Mindnich R, Möller G, Adamski J (2004) The role of 17 beta-hydroxysteroid dehydrogenases. *Mol Cell Endocrinol* 218: 7–20.
 41. Foster PA, Reed MJ, Purohit A (2008) Recent developments of steroid sulfatase inhibitors as anti-cancer agents. *Anticancer Agents Med Chem* 8: 732–738.
 42. Purohit A, Chander SK, Woo LW, Parsons MF, Jhalli R, et al. (2008) Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. *Anticancer Res* 28: 1517–1523.
 43. Brodie A, Sabinis G, Jelovac D (2006) Aromatase and breast cancer. *J Steroid Biochem Mol Biol* 102: 97–102.
 44. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, et al. (2007) 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. *Int J Cancer* 120: 285–291.
 45. Schuster D, Laggner C, Steindl TM, Paluszczak A, Hartmann RW, et al. (2006) Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. *J Chem Inf Model* 46: 1301–1311.
 46. Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, et al. (2007) Dual aromatase-steroid sulfatase inhibitors. *J Med Chem* 50: 3540–3560.
 47. Poirier D (2009) Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. *Anticancer Agents Med Chem* 9: 642–660.
 48. Kruchten P, Werth R, Bey E, Oster A, Marchais-Oberwinkler S, et al. (2009) Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. *J Steroid Biochem Mol Biol* 114: 200–206.
 49. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW (2009) Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. *Mol Cell Endocrinol* 301: 154–157.
 50. Tremblay MR, Boivin RP, Luu-The V, Poirier D (2005) Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol. *J Enzyme Inhib Med Chem* 20: 153–163.
 51. Poirier D, Chang HJ, Azzi A, Boivin RP, Lin SX (2006) Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. *Mol Cell Endocrinol* 248: 236–238.
 52. Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, et al. (2005) E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. *J Med Chem* 48: 5749–5770.
 53. Schwarz S, Thieme I, Richter M, Undeutsch B, Henkel H, et al. (1996) Synthesis of estrogen sulfamates: compounds with a novel endocrinological profile. *Steroids* 61: 710–717.
 54. Poirier D, Ciobanu LC, Berube M (2002) A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives. *Bioorg Med Chem Lett* 12: 2833–2838.
 55. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, et al. (2009) New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. *J Med Chem* 52: 6724–6743.
 56. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, et al. (2002) A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. *Faseb J* 16: 1829–1831.
 57. Berube M, Poirier D (2004) Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling reactions. *Org Lett* 6: 3127–3130.
 58. Brown WM, Metzger LE, Barlow JP, Hunsaker LA, Deck LM, et al. (2003) 17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold. *Chem Biol Interact* 143–144: 481–491.
 59. Gunn D, Akuche C, Baryza J, Blue ML, Brennan C, et al. (2005) 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. *Bioorg Med Chem Lett* 15: 3053–3057.
 60. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, et al. (2008) Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. *J Med Chem* 51: 4685–4698.
 61. Messinger J, Thole H-H, Husen B, Van Steen BJ, Scheider G, et al. (2008) Novel 17beta hydroxysteroid dehydrogenase type I inhibitors. Patent 1685150. WO2004080271A. Patent 1685150 WO2004080271A.
 62. Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, et al. (2005) Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. *J Mol Endocrinol* 35: 89–101.
 63. Leenders F, Tesdorpf JG, Markus M, Engel T, Seedorf U, et al. (1996) Porcine 80-kDa protein reveals intrinsic 17 beta-hydroxysteroid dehydrogenase, fatty acyl-CoA-hydratase/dehydrogenase, and sterol transfer activities. *J Biol Chem* 271: 5438–5442.
 64. Adamski J (1991) Isolation of vesicles mediating the conversion of 17 beta-estradiol to estrone. *Eur J Cell Biol* 54: 166–170.
 65. Poirot O, O'Toole E, Notredame C (2003) Tcoffee@igs: A web server for computing, evaluating and combining multiple sequence alignments. *Nucleic Acids Res* 31: 3503–3506.

66. Lin SX, Han Q, Azzi A, Zhu DW, Gongloff A, et al. (1999) 3D-structure of human estrogenic 17beta-HSD1: binding with various steroids. *J Steroid Biochem Mol Biol* 69: 425–429.
67. Azzi A, Rehse PH, Zhu DW, Campbell RL, Labrie F, et al. (1996) Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol. *Nat Struct Biol* 3: 665–668.
68. Qiu W, Zhou M, Labrie F, Lin SX (2004) Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. *Mol Endocrinol* 18: 1798–1807.
69. Koski KM, Haapalainen AM, Hiltunen JK, Glumoff T (2005) Crystal structure of 2-enoyl-CoA hydratase 2 from human peroxisomal multifunctional enzyme type 2. *J Mol Biol* 345: 1157–1169.
70. Haller F, Moman E, Hartmann RW, Adamski J, Mindnich R (2010) Molecular Framework of Steroid/Retinoid Discrimination in 17beta-Hydroxysteroid Dehydrogenase Type 1 and Photoreceptor-associated Retinol Dehydrogenase. *J Mol Biol*, in press: doi:10.1016/j.jmb.2010.1004.1002.
71. Koczyk G, Wyrwicz LS, Rychlewski L (2007) LigProf: a simple tool for in silico prediction of ligand-binding sites. *J Mol Model* 13: 445–455.